Weekly Investment Analysts’ Ratings Updates for Nuvation Bio (NUVB)

A number of research firms have changed their ratings and price targets for Nuvation Bio (NYSE: NUVB):

• 8/21/2026 – Nuvation Bio is now covered by Cantor Fitzgerald. They set an “overweight” rating on the stock.
• 8/18/2026 – Nuvation Bio is now covered by JPMorgan Chase & Co.. They set an “overweight” rating and a $13.00 price target on the stock.
• 8/7/2026 – Nuvation Bio had its “buy” rating reaffirmed by B. Riley Financial, Inc..
• 8/7/2026 – Nuvation Bio had its price target raised by Royal Bank Of Canada from $19.00 to $20.00. They now have an “outperform” rating on the stock.
• 7/27/2026 – Nuvation Bio had its price target raised by HC Wainwright from $17.00 to $21.00. They now have a “buy” rating on the stock.
• 7/23/2026 – Nuvation Bio had its “outperform” rating reaffirmed by Wedbush. They now have a $11.00 price target on the stock.
• 7/22/2026 – Nuvation Bio had its “outperform” rating reaffirmed by Royal Bank Of Canada.
• 7/17/2026 – Nuvation Bio had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/7/2026 – Nuvation Bio had its price target lowered by Royal Bank Of Canada from $20.00 to $19.00. They now have an “outperform” rating on the stock.
• 7/7/2026 – Nuvation Bio had its price target raised by Truist Financial Corporation from $12.00 to $13.00. They now have a “buy” rating on the stock.
• 7/6/2026 – Nuvation Bio was upgraded by Zacks Research from “strong sell” to “hold”.

Insider Buying and Selling

In other Nuvation Bio news, insider Kerry Wentworth sold 63,000 shares of the business’s stock in a transaction dated Tuesday, June 23rd. The shares were sold at an average price of $6.02, for a total value of $379,260.00. Following the completion of the sale, the insider owned 53,000 shares of the company’s stock, valued at $319,060. The trade was a 54.31% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Gary Hattersley sold 100,000 shares of the stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $7.09, for a total transaction of $709,000.00. Following the transaction, the insider owned 100,000 shares in the company, valued at approximately $709,000. The trade was a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 335,668 shares of company stock valued at $2,128,495 in the last 90 days. 30.11% of the stock is currently owned by corporate insiders.

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.